GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,710.2 (+6.72% day change)
Key ratios
- P/E ratio
- 44.32
- P/B ratio
- 17.06
- ROE (%)
- 45.69
- ROCE (%)
- 49.51
- Debt/Equity
- 0.01
- Dividend yield (%)
- 1.85
- Market cap (₹ Cr)
- 45,912.42
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 10.18 · Beneish M-Score: -2.61
InvestSights quality score
71.6/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Revenue growth: guided 10% minimum, delivered 2.57% (FY26) — missed guidance
- Vaccine business growth: guided 8–10%, delivered 8.6% (Q1 FY26) — met guidance
Latest earnings call (Q2 FY27)
AI summary: The central signal is that GSK India’s portfolio transformation is becoming financially visible without yet weakening reported profitability. Innovation products now contribute 7% of revenue, versus about 3% a year earlier, and generated a quarter of overall growth, while established products delivered mid to high single-digit volume growth. Management has also clarified the…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.